生态评估和分析方法的开发,用于瓦尔萨坦和萨库比特利尔的同时量化:基于相对得分的白度比较研究
Ahmed K Kammoun1, Mostafa A Afify2, Rasha M Youssef2
1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University P.O. Box 80260 Jeddah 21589 Saudi Arabia.
RSC advances
|May 22, 2024
概括
开发了新的可持续的光谱计量方法,可以同时分析瓦尔萨坦 (VAS) 和萨库比特里尔 (SAB). 这些绿色分析技术为药物分析提供了高灵敏度和选择性,促进了更广泛的工业应用.
科学领域:
- 分析化学 分析化学
- 环境科学 环境科学
背景情况:
- 瓦尔萨坦 (VAS) 和萨库比特里尔 (SAB) 联合治疗 (LCZ696) 越来越多地用于高血压和心力衰竭.
- 越来越多的VAS/SAB使用需要开发具有成本效益和可持续的同时量化分析方法.
- 现有的分析方法可能与绿色化学的原则不一致,导致需要环保替代品.
研究的目的:
- 开发和验证高灵敏和选择性的可持续光谱法测量方法,用于同时确定瓦尔萨坦和萨库比特里尔.
- 通过使用既定指标来评估拟议的分析方法的绿色性和可持续性.
- 将开发方法的性能和环境影响与现有技术进行比较.
主要方法:
- 开发了两种同步的光谱度测量方法:一种是利用一阶光谱导数,另一种是采用双波长数学方法.
- 方法根据国际协调理事会 (ICH) 的指导方针进行验证,为VAS和SAB建立线性范围.
- 使用分析生态尺度 (AES),绿色分析程序指数 (GAPI) 和分析绿色度量 (AGREE) 等工具评估分析绿色度.
- 用白度RGB 12算法进行比较评估,对方法可持续性的评估.
主要成果:
- 两种开发的方法都显示出高灵敏度和选择性,用于同时进行VAS和SAB分析.
- 在两种方法中,两种药物的线性校准曲线都在指定范围内获得 (例如,VAS:60-200 ng mL-1;SAB:17-190 ng mL-1).
- 提出的方法显示出出色的绿色配置文件,由AES,GAPI和AGREE评估证实.
- 使用白度算法进行的比较分析在可持续性和分析性能方面对拟议的方法进行了高度排名.
结论:
- 开发的混合光谱法具有高度灵敏性,选择性和可持续性,可同时确定瓦尔萨坦和萨库比特里尔.
- 与之前报告的技术相比,这些方法在分析性能和环保性方面具有显著的优势.
- 这些绿色分析方法的可负担性和简单性使它们适合广泛的工业应用,特别是在发展中国家.
相关概念视频
Structure-Activity Relationships and Drug Design
699
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
699
Noncompartmental Analysis: Miscellaneous Pharmacokinetic Parameters
89
The noncompartmental approach is a widely used method in pharmacokinetics to assess drugs' behaviors in the body. It considers several factors, including clearance, bioavailability, and total volume of distribution.
One key aspect of the noncompartmental approach is determining a drug's total clearance. This can be done by dividing the drug dose by the area under the concentration-time curve from zero to infinity. The area under the concentration-time curve represents the drug's...
One key aspect of the noncompartmental approach is determining a drug's total clearance. This can be done by dividing the drug dose by the area under the concentration-time curve from zero to infinity. The area under the concentration-time curve represents the drug's...
89
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
60
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
60
Drug Concentrations: Measurements
358
Drug concentration is the quantity of a drug present in a biological sample. Measuring drug amounts in biological samples allows the clinician to understand how a drug is absorbed, distributed, metabolized, and excreted. Samples can be obtained through invasive or non-invasive methods. Invasive techniques involve surgical or parenteral interventions to gather blood, cerebrospinal fluid, or tissue biopsy. Conversely, non-invasive approaches provide samples like urine, feces, and saliva.
Plasma...
Plasma...
358
Dose-Response Relationship: Potency and Efficacy
4.4K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.4K


